1. Drug company under fire after revealing dengue vaccine may harm some;Grady;The New York Times (New York),2017
2. Zambrano BM, Arredondo JL, Capeding MR, et al. Long term safety of the recombinant live-attenutated chimeric yellow efever-dengue virus tetravalent dengue vaccine (CYD-TDV) in pahse III efficacy trials in Asia and Latin America. American Society of Tropical Medicine and Hygiene Annual Meeting; Batimore, MA, USA; Nov 5–9, 2017. LB-5328.
3. Economic and disease burden of dengue in southeast Asia;Shepard;PLoS Negl Trop Dis,2013
4. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial;Capeding;Lancet,2014